These results suggest that the combinatorial approaches, at least for Barasertib + Cetuximab and Ispinesib + Cetuximab combinations, exhibit the ability to maintain long-term cellular cytotoxicity, preventing the proliferation of cancer cells, supporting the therapeutic promise of combining EGFR inhibition with Aurora-B or KSP inhibition, and to a lesser extent with MPS-1 inhibition, in oral cancer treatment. Here, EGFR is linked to lip and oral cavity carcinoma.